Literature DB >> 28509937

Next generation sequencing is informing phenotype: a TP53 example.

R O'Shea1, R Clarke2, E Berkley2, C Giffney3, M Farrell3, E O'Donovan2, D J Gallagher3,2.   

Abstract

The increased availability of next generation sequencing (NGS) and multi gene panel testing has resulted in more frequent TP53 testing of families that do not meet classic testing criteria. We investigated testing criteria, family history and result outcome in a cohort of Irish probands undergoing TP53 full sequencing. All TP53 test requests processed through the national genetic testing laboratory between 2012 and 2014 were retrospectively reviewed. Personal and family cancer histories were collected, including tumour type and age at diagnosis, from two adult cancer genetic services in Ireland. Association between Li Fraumeni syndrome (LFS) or Li Fraumeni like syndrome (LFL) criteria and test result was examined. One hundred and 35 TP53 test requests were identified. Family history data and test results were available on 123 of the TP53 test requests (118 female; 5 male). 59/123 (48%) did not meet classic LFS or LFL criteria. Two individuals from this group harboured pathogenic TP53 mutations, giving a 3% mutation detection rate in those not meeting testing criteria. Both were female and had a personal history of early onset bilateral breast cancer with no reported LFS cancers in the family. 64/123 (52%) met LFS or LFL criteria and were all TP53 negative. 37/64 (57.8%) met Chompret criteria, 19/64 (29.7%) met Eeles and 7/64 (10.9%) met Eeles and Chompret and 1/64 (1.6%) met Classic LFS criteria. Stringent testing criteria miss germline mutations in TP53. Broadening the criteria for TP53 testing may improve our understanding of the phenotype and penetrance in the association syndrome.

Entities:  

Keywords:  Li Fraumeni; Multigene panels; Testing criteria

Mesh:

Substances:

Year:  2018        PMID: 28509937     DOI: 10.1007/s10689-017-0002-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Authors:  Judy Mouchawar; Christopher Korch; Tim Byers; Todd M Pitts; Efang Li; Margaret R E McCredie; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?

Authors:  Susan M Domchek; Angela Bradbury; Judy E Garber; Kenneth Offit; Mark E Robson
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

3.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.

Authors:  Fiona Lalloo; Jennifer Varley; Anthony Moran; David Ellis; Lindsay O'dair; Paul Pharoah; Antonis Antoniou; Roger Hartley; Andrew Shenton; Sheila Seal; Barbara Bulman; Anthony Howell; D Gareth R Evans
Journal:  Eur J Cancer       Date:  2006-04-27       Impact factor: 9.162

4.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

Review 5.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

7.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

8.  p53 mutations in breast cancer.

Authors:  C Coles; A Condie; U Chetty; C M Steel; H J Evans; J Prosser
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  Routine TP53 testing for breast cancer under age 30: ready for prime time?

Authors:  Jeanna M McCuaig; Susan R Armel; Ana Novokmet; Ophira M Ginsburg; Rochelle Demsky; Steven A Narod; David Malkin
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

View more
  2 in total

1.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

2.  Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.

Authors:  Jacopo Azzollini; Milena Mariani; Bernard Peissel; Siranoush Manoukian
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.